Morehouse School of Medicine’s strong emphasis on strengthening primary care, promoting prevention and early detection, and working to reduce and eliminate health disparities has made the institution a unique academic medical center in the United States – and the world.
The biotechnologies developed by MSM researchers are targeted to prevent, diagnose and treat chronic diseases like HIV/AIDS and other infectious diseases, cancer, cardiovascular disease, metabolic and neurological disorders. Technology transfer will continue to be an important process for creating new and existing research and development efforts as well as a driving force for national and regional economic development.
Morehouse School of Medicine invites partnerships with the institution and its technology commercialization opportunities. Selected technologies for licensing are summarized below:
Method for Identifying Salt-Sensitive Persons. It is the purpose of this invention to find an economical and rapid means of identifying salt-sensitive persons who may have or can be expected to develop hypertension.
Tumor Cytotoxicity Induced by Modulators of the CXCR4 Receptor. This invention relates to the use of Gp120 and Nef proteins of retroviruses as therapeutic agents against carcinomas.
Anti–Chemokine and–Associated Receptor Antibodies and Uses for Inhibition of Inflammation. The invention describes methods of identifying or treating a person with certain inflammatory diseases, e.g., chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), interstitial cystitis.
Trypanosome Derived Apoptotic Factors (TAF). This invention relates to the delivery of neurotrophic therapies as new treatment alternatives for central nervous system disorders that account for more hospitalizations, long-term care, and chronic suffering than nearly all other disorders combined.
Modulating Vaccine Against HIV-1 Nef Protein Induced Lymphocyte Depletion. The invention comprises a therapeutic vaccine that will provide protection against Nef-mediated pathogenesis, which causes T cell depletion seen in full-blown AIDS.
Neuregulins as Regulators of Stem Cell Migration. This invention relates to the administration of neuregulins (growth factors) that can facilitate neuronal stem cell migration and neurogenesis to repair damage to the brain following stroke or other neurodegenerative disorders.
Rad Attenuation of Vascular Lesion Formation and Treatment of Vascular Diseases. It is the purpose of this technology to provide a means for preventing and treating restenosis and atherosclerosis. The method of the invention comprises administration of the Rad gene either systemically or by means of a drug-eluting stint.
Splice Variants of BRCA1. This discovery will enhance detection and identification of agents capable of modulating the amount or activity of the Breast Cancer Susceptibility Gene (BRCA1) proteins in cells.
Novel Nanoparticles for Delivery of Inert and Biologically Active Agents. This technology enables the use of therapeutic or diagnostic molecules to be delivered and released in a controllable fashion to targeted sites affected by inflammation, infectious diseases, and cancer.
For more information, contact Sandra Harris-Hooker, Ph.D., vice president and senior associate dean for Research Affairs, at 404-752-1725 or sharris-hooker@msm.edu.